Bed wetting Desmopressin is used to treat
nocturnal enuresis (bedwetting). It is usually prescribed in the form of desmopressin acetate, by mouth. Children taking DDAVP have 2.2 fewer wet nights per week and are 4.5 times more likely to sleep without disruption compared with placebo.
Nocturia In 2017, the FDA approved desmopressin has some benefit for adults who have problems with
nocturia (having a need to wake up at night for urination).
Bleeding disorders Desmopressin (DDAVP) is usually the first line treatment for mild to moderate type 1
von Willebrand disease. It is not recommended in severe disease or in those with abnormal
factor VIII. Usefulness in type 2A, 2M, or 2N von Willebrand disease is variable. Generally not recommended in 2B and type 3 von Willebrand disease. Desmopressin is only recommended in mild hemophilia A. It may be used both for bleeding due to trauma or to try to prevent bleeding due to surgery. It is not effective in the treatment of hemophilia B (factor IX deficiency) or severe hemophilia A. May also be used in
uremia induced bleeding.
Diabetes insipidus Desmopressin is used in the treatment of
central diabetes insipidus (DI) as a replacement for endogenous
antidiuretic hormone (ADH) that is in insufficient quantity due to decreased or non-existent secretion or production of ADH by the posterior pituitary or hypothalamus, respectively. It is also used in the
diagnostic workup for diabetes insipidus, in order to distinguish central from
DI due to the kidneys. Desmopressin is not effective at treating nephrogenic DI, thus a positive response is generally indicative of central DI. ==Side effects==